NRG-GY035: A RANDOMIZED PHASE III TRIAL OF CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB VERSUS CARBOPLATIN, PACLITAXEL, BEVACIZUMAB VERSUS CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB, BEVACIZUMAB IN THE TREATMENT OF pMMR, TP53 MUTATED ADVANCED OR RECURRENT ENDOMETRIAL CANCER
- Title
- A RANDOMIZED PHASE III TRIAL OF CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB VERSUS CARBOPLATIN, PACLITAXEL, BEVACIZUMAB VERSUS CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB, BEVACIZUMAB IN THE TREATMENT OF pMMR, TP53 MUTATED ADVANCED OR RECURRENT ENDOMETRIAL CANCER
- Principal Investigator
- Pfaendler, Krista
- Phase
- III (Cancer Control)
- Age Group
- Adult
- Applicable Disease Sites
- Gynecologic Cancers
- Participating Institutions
- Mary Babb Randolph Cancer Center
- Contacts
- Sabrina Rexroad, RN
- Research Nurse
- Email: sabrina.rexroad1@wvumedicine.org
- Valli White, RN
- Research Nurse
- Phone: +1 304-264-1220
- Email: valli.white@wvumedicine.org
- Layla Tannoury
- Clinical Research Specialist
- Phone: +1 304-424-2585
- Email: layla.tannoury@wvumedicine.org
- Nnennaya Opara
- Clinical Research Specialist
- Phone: +1 681-342-1000
- Email: nnennaya.opara1@wvumedicine.org
- Jill Stone, LPN
- Research Specialist
- Phone: +1 304-634-4417
- Email: jill.stone@hsc.wvu.edu